Article Text

PDF
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up
  1. Nicoletta Colombo*,
  2. Carien Creutzberg,
  3. Frederic Amant,
  4. Tjalling Bosse§,
  5. Antonio González-Martín,
  6. Jonathan Ledermann,
  7. Christian Marth#,
  8. Remi Nout**,
  9. Denis Querleu††,
  10. Mansoor Raza Mirza‡‡ and
  11. Cristiana Sessa§§
  1. *Division of Medical Gynecologic Oncology, European Institute of Oncology and University of Milan-Bicocca, Milan, Italy;
  2. Department of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands;
  3. Department of Gynecological Oncology, University Hospital Leuven, Leuven, Belgium and Center for Gynecological Oncology Amsterdam (CGOA), Antoni van Leeuwenhoek, Amsterdam, The Netherlands;
  4. §Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands;
  5. Medical Oncology Department, GEICO and MD Anderson Cancer Center, Madrid, Spain;
  6. Department of Oncology and Cancer Trials, UCL Cancer Institute, London, United Kingdom;
  7. #Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria;
  8. **Department of Radiotherapy, Leiden University Medical Center, Leiden, The Netherlands;
  9. ††Department of Surgery, Institut Bergonié, Bordeaux, France and Gynecology and Obstetrics Department, McGill University Health Centre, Montreal, Quebec, Canada;
  10. ‡‡Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; and
  11. §§Department of Medical Oncology, Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland.
  1. Address correspondence and reprint requests to Prof Nicoletta Colombo, ESMO Guidelines Committee, ESMO Head Office, Via L. Taddei 4, CH-6962 Viganello-Lugano, Switzerland. E-mail: clinicalguidelines@esmo.org.

Abstract

Abstract The first joint European Society for Medical Oncology (ESMO), European SocieTy for Radiotherapy & Oncology (ESTRO) and European Society of Gynaecological Oncology (ESGO) consensus conference on endometrial cancer was held on 11–13 December 2014 in Milan, Italy, and comprised a multidisciplinary panel of 40 leading experts in the management of endometrial cancer. Before the conference, the expert panel prepared three clinically-relevant questions about endometrial cancer relating to the following four areas: prevention and screening, surgery, adjuvant treatment and advanced and recurrent disease. All relevant scientific literature, as identified by the experts, was reviewed in advance. During the consensus conference, the panel developed recommendations for each specific question and a consensus was reached. Results of this consensus conference, together with a summary of evidence supporting each recommendation, are detailed in this article. All participants have approved this final article.

  • Endometrial neoplasms
  • Practice guideline
  • Consensus
  • Treatment
  • Adjuvant
  • Surgery

Statistics from Altmetric.com

Footnotes

  • See appendix for members of the ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group.

  • These Guidelines were developed by the European SocieTy for Medical Oncology (ESMO), the European Society of Gynaecological Oncology (ESGO), and the European SocieTy of Radiotherapy and Oncology (ESTRO), and are published jointly in the Annals of Oncology, the International Journal of Gynecological Cancer and Radiotherapy & Oncology. The three societies nominated participants who attended the consensus conference and co-authored the final manuscript.

  • Funding: All costs relating to the consensus conference were covered from the European Society for Medical Oncology central funds. There was no external funding of the event or manuscript production.

  • Disclosures: Frederic Amant (senior investigator for the Research Fund Flanders [FWO]), Nicoletta Colombo (consultancy - Roche, Astra Zeneca), Luis Chiva de Agustín (speaker for Roche and Takeda), Günter Emons (research grants from Aeterna Zentaris and Astra Zeneca), Christian Kurzeder (research funding from Roche, speaker for Roche), Fabrice Lécuru (research grants from Intuitive Surgicals, advisory board for Roche), Jonathan Ledermann (advisory boards for AstraZeneca, Clovis Oncology, Merck/MSD, Bayer, Oxigene), Helga Salvesen (pending intellectual property rights for some aspects relating to STMN/pSTMN1 as a prognostic marker for endometrial cancer [US 127962,946(HS) and US 147155,412(HS)]). All remaining authors have declared no conflicts of interest.

  • Supplemental digital content is available for this article. Direct URL citation appears in the printed text and is provided in the HTML and PDF versions of this article on the journal’s Web site (www.ijgc.net).

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.